XML 63 R45.htm IDEA: XBRL DOCUMENT v3.19.3
Synthetic Genomics Asset Acquisition (Details) - USD ($)
3 Months Ended 9 Months Ended
Feb. 28, 2020
Jan. 01, 2020
Feb. 28, 2019
Jan. 01, 2019
Dec. 20, 2018
Feb. 28, 2018
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Jan. 01, 2021
May 09, 2019
May 08, 2019
Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Issuance of common stock and conversion of deferred consideration for asset acquisition                 $ 1,462,000          
Derivative liability, fair value                           $ 1,117,000
Derivative liability                           $ 1,117,000
Gain on derivative liability               $ (105,000) 1,117,000 $ (241,000)        
Interest expense             $ 190,000 $ 307,000 726,000 676,000        
Synthetic Genomics Inc [Member] | C3J [Member]                            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Cash paid for productive assets           $ 8,000,000                
Cash paid acquisition of assets     $ 1,000,000 $ 1,000,000 $ 1,000,000 1,000,000                
Issuance of common stock and conversion of deferred consideration for asset acquisition           27,000,000                
Percentage of fully diluted capitalized for issuance of common stock         10.00%                  
Maximum potential milestone payments         $ 39,500,000                  
Derivative liability, fair value                       $ 0 $ 2,800,000  
Derivative liability             2,900,000   2,900,000          
Gain on derivative liability                 2,000,000          
Gain on restructuring                 0          
Interest expense                 $ 716,000 $ 676,000        
Equity payment obligation                 516,976          
Synthetic Genomics Inc [Member] | C3J [Member] | Scenario, Plan [Member]                            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Cash paid acquisition of assets $ 1,000,000 $ 1,000,000       $ 5,000,000                
Payable at three years from closing / on January 31, 2021                     $ 2,000,000      
Synthetic Genomics Inc [Member] | C3J [Member] | Fair Value, Measurements, Nonrecurring [Member]                            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                            
Fair value of assets acquired             $ 6,800,000   $ 6,800,000